Pancreatic Cancer Surgery Outcomes: Sex & Obesity
Okay, hear’s a breakdown of the provided text, focusing on the key findings and study details.
Main Findings:
* Sex and Obesity Impact Outcomes: The study found that outcomes for pancreatic adenocarcinoma (PDAC) patients after surgery differed based on both biologic sex and obesity status.
* Obese Females Have Best Outcomes: Obese females had the most favorable outcomes, with superior overall survival (median OS of 37 months) and the lowest rates of liver recurrence (13% at 12 months, 15% at 24 months).
* Obese Males Have Worst Outcomes: Obese males had significantly worse overall survival compared to obese females (HR 1.56, 95% CI 1.12-2.18, P = .009).
* Possible Protective Mechanism in obese Females: The authors hypothesize that there may be something protective in the obese female liver or metabolism that limits cancer spread or enhances chemotherapy effectiveness. They also suggest hormonal mechanisms could be involved.
Study Methodology & Patient Characteristics:
* Type of Study: Retrospective observational analysis.
* Data Source: Data from patients treated at Memorial Sloan Kettering Cancer Center between 2012 and 2022.
* Patient Population: 939 patients with resected pancreatic cancer (PDAC) who underwent upfront surgery.
* Median Age: 70 years.
* Surgery Type: 73% underwent pancreaticoduodenectomy.
* BMI Categories: Patients were categorized based on BMI using CDC/WHO guidelines:
* Underweight (<18.5)
* Normal (18.5-24.9)
* Overweight (25.0-29.9)
* Obese Class I (30.0-34.9)
* Obese Class II (35.0-39.9)
* Obese Class III (≥40)
* Outcome Measures: Overall survival (OS) and liver recurrence.
* Statistical Analysis: Univariate and multivariate models were used to evaluate associations between factors and OS.
In essence, the study suggests a complex interplay between sex, obesity, and pancreatic cancer outcomes, with obese females appearing to have a survival advantage and obese males facing a greater risk.